Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the open-label, dose-escalation study is to investigate the safety
of single-dose monotherapy and repeated-dose of KHK2375 combined with exemestane in female
subjects with advanced or recurrent breast cancer. The secondary objective is to investigate
the pharmacokinetics and efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.